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1. Introduction 
17-estradiol is the most potent form of naturally occurring estrogen secreted during the 
reproductive years (Andersson 2000; Paoletti 2001). It is an essential steroid hormone that 
regulates numerous endocrine functions through binding to two estrogen receptor (ER) 
isoforms, i.e., ER and ER. The concentration of these receptor subtypes and the 
corresponding cofactors vary with tissue types, leading to tissue specific regulation of 
estrogen response and toxicity. However, the content of ER in tissues has been assumed to 
be time-invariant (Plowchalk 2002). This indicates that multiple or prolonged exposure to E2 
of ER in various tissues should not alter physiological and toxic responses.     
Estradiol (E2) is carried in the plasma in two forms, bound to plasma binding proteins (95-98 
%) and unbound form or free estradiol (2-5 %) (Dunn 1983; Pardridge 1986; Plowchalk 
2002). Both unbound and bound forms of E2 manifest pharmacological actions. Bound form 
acts as a reservoir for E2 in blood circulation (Plowchalk 2002). After menopause the primary 
circulating estrogen is estrone, which is less biologically active than E2 (Kuhl 2005; Margolis 
2010). Thus, E2 is usually administered to control early menopausal symptoms such as hot 
flashes and night sweats. For long-term administration E2 can prevent cardiovascular 
diseases and osteoporosis (Andersson 2000; Paoletti 2001). After administered E2 reaches to 
blood circulation, it rapidly undergoes chemical conversions to estrone, driven in part by 
the body’s need to maintain homeostasis. Other estrogens in conjugated forms either 
equine- or synthetic-derived also exist as a balance between the ingested form and estrone at 
steady state in the body. Margolis (Margolis 2010) indicated that the conversion of E2 to 
estrone was reversible reaction. Therefore, estrone plays as a hormonally inert reservoir, 
capably converting to E2. These conversions make the administered estrogen 
indistinguishable from naturally occurring E2 in the body.    
However, hormone therapy is not without risks. The FDA and several professional 
organizations currently recommend prescribing the lowest effective dose for the shortest 
duration of time in accordance with treatment goals for an individual woman (Mueck 2003; 
Utian 2008; Margolis 2010). Nowaday there are a wide variety of estrogen products, 
including oral tablets, transdermal patches, and topical sprays, gels, and lotions, as well as 
vaginal creams, tablets, and rings. Selection of an appropriate product is often based on 
patient’s preference. Oral estrogen dosage form is preferred due to its convenient route of 
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administration. To improve outcome of estrogen therapy, formulation properties and 
product pharmacokinetics should be considered for choosing an appropriate product. 
2. Biopharmaceutics and pharmacokinetics of estrogen products 
Oral administration of estrogen in tablet dosage form is the most favorable form for 
estrogen replacement therapy. The oral bioavailability of estrogen is dependent on its 
solubility in gastrointestinal (GI) fluid and permeability across membrane of endothelial cell 
lining in the gut wall. Unconjugated estrogens are hydrophobic molecules with low 
solubility in GI fluid. To improve the bioavailability their dissolution has to be increased. 
The methods normally used to enhance estrogen dissolution are chemical modification and 
reduction of the particle size.  
Modification of chemical structure by conjugating with hydrophilic groups via esterification 
such as estradiol acetate and sulfonation such as sulfonated estrogens can improve drug 
dissolution. Conjugated estrogens exhibit better solubility than unconjugated form. 
However, most of conjugated estrogens have low affinity for ER. Thus, oral administration 
of conjugated form such as sulfonated estrogens may reduce undesired stimulation of ER 
within the GI tract. Since sulfonated estrogens are carried to target tissues, they are 
enzymatically hydrolyzed and then converted to bioactive estrogens (Margolis 2010). 
Similarly, estradiol acetate is also hydrolyzed in plasma and tissue and then transforms to 
active estrogen (Iwamori 2005; Margolis 2010). 
Using micronized form of estrogen as an active ingredient in tablet formulation can improve 
estrogen dissolution by increasing surface area exposure to the dissolution medium. This 
phenomenon can be described by the Noyes-Whitney Equation (Shargel 1999); 
 ௗ஼ௗ௧ = ஽஺௛ ሺܥ௦ − ܥሻ (1) 
where  ௗ஼ௗ௧ =	 rate of drug dissolution at time t, D = diffusion rate constant, A = surface area 
of the drug particles, Cs = concentration of drug in the stagnant layer (equal to solubility of 
the drug), C = concentration of drug in bulk solution, h = thickness of the stagnant layer.  
From Noyes-Whitney equation, rate of drug dissolution at time t ቀௗ௖ௗ௧ቁ is directly increased as 
the surface area of the drug particles (A) is increased. Using micronized estrogen in tablet 
formulation results in the increase of surface area of the drug particles and consequently 
increases estrogen dissolution. Furthermore, design of tablet disintegration by using specific 
disintegrants in the formulation affects the duration to allow estrogen to dissolve in the GI 
fluid and then absorb into the blood stream. Product design potentially affects the 
bioavailability of estrogen. 
During hormone therapy estrogens are orally administered once a day according to 
prolonged terminal elimination half-life (Plowchalk 2002). Oral dosage form of estrogens is 
often formulated in immediate-release tablet. This kind of product rapidly releases estrogen 
after administered. Due to rapid absorption of estrogens into the blood circulation (Margolis 
2010), plasma estrogen concentration versus time profile reveals peaks and troughs pattern. 
Therefore, oral administration of immediate-release estrogen tablets has the potential to 
produce high spikes in blood levels, which possibly lead to estrogen-excess symptoms such 
as breast tenderness, headaches, nausea, vomiting, mood swings, bleeding, or spotting. 
Boyd et al. (Boyd 2003; Margolis 2010) reported the decrease in maximum concentration 
ranging from 3% to 36% in a fed state as compared to a fasting state in subjects, taking 
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estrogen tablet with a high-fat meal. This report met an agreement with the reason of some 
patients undergone breakthrough hot flashes when taking their estrogen products with food 
(Margolis 2010). In addition, the variation of estrogen concentration in blood level probably 
comes from intestinal and hepatic first-pass metabolism of orally administered estrogen 
(Meli 1968; Longcope 1985; Plowchalk 2002). This characteristic results in low oral 
bioavailability of estrogen, which is only 2-5 % (Bawaarshi-Hassar 1989; Kuhnz 1993; 
Plowchalk 2002). Thus, trend of estrogen product development has been tempted to 
abandon oral administration and shifted to non-oral administrations. 
Non-oral estrogen administration avoids hepatic first-pass effect, allowing smaller dose to 
be used and preventing undesirable changes from liver stimulation (Pentikis 1998; Munoz 
1999; Rohr 1999; Andersson 2000; Paoletti 2001; Anderson 2002). However, desirable 
estrogen product is not only containing the lowest effective dose but also maintaining 
estrogen in blood level within a therapeutic range over a conveniently long dosing interval. 
These characteristics ensure adequate concentration of estrogen in blood for preventing both 
daytime hot flashes and night sweats, while not reaching overly high or peaky blood levels 
that may cause adverse events, such as breast tenderness, headache, nausea, vomiting, 
mood swings, bleeding, or spotting. 
In the past, the only way to eliminate the peak and trough plasma levels of drug therapy was 
to deliver continuous intravenous (IV) infusion to a patient at a constant rate based on 
pharmacokinetics of the drug. However, this kind of drug administration requires health care 
professionals to monitor drug concentration in the plasma, thus usually cannot be performed 
at home. To alleviate this problem, various types of controlled-release drug delivery system 
have been developed to release the drug at a constant rate, replacing the administration via 
continuous IV infusion. In 1937, Parks and Dansby had formulated compressed pure 
crystalline estrogen pellets and administered them by subcutaneous injection to livestock. The 
results showed a continuous release of hormone over 3 months in several animals. Their work 
was presented at the Royal Society of Medicine in London. This led to a widespread idea of 
hormonal implantation in animals, which became the standard practice in the 1950s (Dash 
1998). This discovery sparked an interest area of implantable drug delivery systems, leading to 
extended studies and continuous discoveries until the present time. 
Implantable drug delivery systems have basically been classified into two major classes, i.e., 
drug implants and implantable pumps containing the drug. The first class utilizes various 
types of polymer matrices and polymeric membranes to control the kinetics of drug release 
from the delivery systems (Danckwerts 1991; Dash 1998). The second class consists of 
mechanical pump-type implants, which utilize an infusion pump-type action to control 
release of the drug. For estrogen therapy, the goal of the delivery system is to release 
estrogens at a constant rate throughout an intended period of time. Controlled release of 
estrogen products either transdermal patches or vaginal rings utilize polymer matrices 
and/or polymeric membranes as rate-controlling element similar to drug implants. To 
clearly understand how polymer matrices and polymer membranes can facilitate the release 
of estrogen, the fundamentals of rate-controlling drug delivery should be addressed. 
3. Basic concepts of rate-controlled estrogen delivery 
The majority of recent literatures have been focused on sustained-release and controlled-
release drug delivery systems. Sustained-release drug product is referred to a dosage form 
formulated to retard the release of a therapeutic agent. Thus, the drug in the systemic 
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circulation is delayed the onset, prolonged its plasma concentration and provided longer 
duration of action (Chien 1992). On the other hand, controlled-release drug product is 
pointed to the delivery system giving a release profile not only predictable kinetically but 
also reproducible from one unit to another (Chien 1982; Chien 1989; Chien 1992). 
Basic principles in the rate-controlled drug released from both polymer matrix and 
polymeric membrane is governed by Fick’s laws of diffusion (Grant 1968; Chien 1992), 
which define the flux of diffusion ሺܬ஽ሻ across a plane surface of unit area as shown; 
 ܬ஽ = −ܦ ௗ௖ௗ௫ (2) 
where D is the diffusivity of drug molecule in a medium of solid, solution, or gas, ቀௗ௖ௗ௫ቁ is the 
concentration gradient of the drug molecule across a diffusional path with thickness dx, and 
a negative sign is used to define the direction of diffusion from a region with high 
concentration to a region with low concentration. The drug concentration gradient acts as 
the energy element for the diffusion of drug molecules. 
In order to identify the mechanism of drug release, governed by Fick’s laws of diffusion, the 
following assumptions need to be established (Chien 1992); 
1. Dissolution of drug crystals into their surrounding medium is the first step of the drug 
release process.  
2. A pseudo-steady state exists in the process of controlled drug release. 
3. The diffusion coefficient of a drug molecule in a given medium is invariable with time 
and distance. 
4. The interfacial partitioning of a drug molecule from polymer toward solution is related 
to its solubility in polymer ൫ܥ௣൯ and in solution ሺܥ௦ሻ as defined by 
 ܭ = ஼ೞ஼೛ (3) 
where K is defined as the partition coefficient. 
Kinetically released of drug molecules from these types of rate-controlled drug delivery 
should be illustrated at each mechanism of drug release. 
3.1 Polymer membrane permeation-controlled drug release 
Polymer membrane permeation-controlled drug release has been appeared in a 
pharmaceutical dosage form in which a drug is totally or partially encapsulated within a drug 
reservoir compartment. The drug reservoir may exist in solid, suspension, or solution forms. 
The encapsulation of drug formulation inside the reservoir compartment is performed by 
spray coating, injection molding, hot-melt extrusion, microencapsulation, or other techniques. 
The examples of this kind of rate-controlled drug delivery system are Progestasert IUD, an 
intrauterine device and Norplant, subdermal implant. Progestasert IUD contains a suspension 
of progesterone crystals in silicone medical fluid, encapsulated in a nonporous membrane of 
ethylene vinyl acetate copolymer in a T-shaped device. This product can continuously release 
progesterone in the uterine cavity at rate of at least 65 g/day for a year (Chien 1992). For 
Norplant, the active drug is levonorgestrel, encapsulated in nonporous silicone medical-grade 
tubing with both ends sealed with medical-grade adhesive silicone. The development of this 
product has been found in 2 generations. The first is composed of 6 units of levonorgestrel 
crystals encapsulated in silicone tubes and the second is composed of 2 units of silicone tubes 
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containing levonorgestrel dispersing in silicone elastomer matrix inside. Both are designed to 
continuously liberate the active drug at a daily dosage rate of 30 g for up to 7 years (Croxatto 
1981; Weiner 1981; Diaz 1982; Segal 1983; Chien 1992). 
The release process begins on the outermost layer of drug particles dissociating themselves 
from the crystal state and then dissolving in the surrounding medium, partitioning and 
diffusing through the polymer structure, and finally partitioning into the elution medium 
surrounding the device. During the device is sink in the surrounding medium, the 
hydrodynamic diffusion layer occurs on the immediate surface of the device.  Therefore, the 
diffusion path length in which drug molecules diffuse across under a concentration gradient is 
the addition of the thickness of polymeric membrane and the hydrodynamic diffusion layer. 
The cumulative amount of drug (Q) released from a unit surface area of a polymer 
membrane permeation-controlled drug delivery system is expressed as shown (Chien 1992); 
 ܳ = ஼೛௄஽೏஽೛௄஽೏௛೛ା஽೛௛೏ ݐ − ஽೛஽೏௄஽೏௛೛ା஽೛௛೏ ׬ ܥ௕ሺ௧ሻ௧଴ ݀ݐ (4) 
where Cp is the drug solubility in the polymer, K is the partition coefficient as defined by 
Equation (3), Dp and Dd are the drug diffusivities in the polymer membrane with thickness 
hp and in the hydrodynamic diffusion layer with thickness hd, respectively. Cb(t) is the 
concentration of drug in the interface of diffusion layer/ bulk solution, t is time, and dt is a 
differential length of time. 
In the case of sink condition throughout the course of controlled drug release, the saturated 
concentration of drug in the solution (Cs) is much higher than the concentration of the drug 
in the bulk solution (Cb(t)); Cs >> Cb(t) or Cb(t)  0. Thus, Equation (4) can be reduced to 
 ܳ = ஼೛௄஽೏஽೛௄஽೏௛೛ା஽೛௛೏ ݐ (5) 
The rate of drug released from this system can be defined by rearrangement of Equation (5) 
into 
 ொ௧ = ஼೛௄஽೏஽೛௄஽೏௛೛ା஽೛௛೏ (6) 
Equation (6) indicates that the rate of drug release per unit time is equal to a constant value, 
i.e., the solubility of drug in the polymer, the partition coefficient, the diffusivity of drug 
molecule, and the thickness of the rate-controlling membrane. This implies that the polymer 
membrane permeation-controlled drug delivery gives a constant drug release profile. 
Equation (6) has considerably described the release of progesterone from Progestasert IUD 
(Chien 1992). 
In case of a thick polymer membrane (hp) and/or extremely low diffusivity of drug 
molecules in a polymer (Dp), which is dependent on the type of polymer material, the term 
of KDdhp is much higher than the term of Dphd. Thus, Equation (6) can be simplified to 
 ொ௧ = ஼೛஽೛௛೛  (7) 
Under this condition the rate of drug release is a function of the solubility and diffusivity of 
drug in the polymer and is inversely proportional to the thickness of the polymer 
membrane. So the release of drug molecules is governed by the membrane-modulated 
permeation process. 
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In case of a very low interfacial partition coefficient (K) or a thick hydrodynamic diffusion 
layer (hd), in which a condition is little movement of the surrounding medium, the KDdhp 
term is significantly smaller than the Dphd term. Equation (6) can be reduced to 
 ொ௧ = ஼೛௄஽೏௛೏  (8) 
From Equation (2), since CpK = Cs, Equation (8) can be rewritten as; 
 ொ௧ = ஼ೞ஽೏௛೏  (9) 
Under this condition the rate of drug release is a function of drug solubility in the surrounding 
medium and drug diffusivity in the hydrodynamic diffusion layer and is inversely 
proportional to the thickness of the hydrodynamic diffusion layer. Thus, the release of drug 
molecules is governed by the diffusion layer-limiting partition-controlled process. 
From the principle of controlled release of drug from a dosage form in which the drug is 
encapsulated inside the polymer membrane, solubility of the drug strongly affects the rate 
of drug release. Under the condition in which the polymeric membrane plays the leading 
role in modulation of drug release, drug solubility in that polymer is a significant factor 
influencing the rate of drug release. On the other hand, under the condition of the 
hydrodynamic diffusion layer-limiting partition-controlled process, drug solubility in the 
surrounding medium affects the rate of drug release. Thus, an alteration in drug solubility 
either in polymer membrane or in the surrounding medium can also affect the rate of drug 
released from this kind of drug delivery system. 
3.2 Polymer matrix diffusion-controlled drug release 
Delivery system, controlling drug release by polymer matrix diffusion-controlled drug 
release, is prepared by homogeneously dispersing drug particles in a rate-controlling 
polymer matrix. The drug dispersion in the polymer matrix can be produced by dissolving 
the drug and the polymer in an appropriate solvent, followed by solvent evaporation at an 
elevated temperature and/or under a vacuum, or mixing finely ground drug particles with 
a rubbery polymer at an elevated temperature. The drug-polymer dispersion is then 
compressed, molded, or extruded to form a drug delivery device of various shapes and sizes 
designed for specific application. 
An example of this type of drug delivery system is Compudose subdermal implant, 
fabricated by dispersing micronized estradiol (E2) crystals in a viscous silicone elastomer 
and then coating the E2-dispersing polymer around a rigid (drug-free) silicone rod by 
extrusion to form a rod-shaped implant. This product has been used for growth promotion 
in steers. It can release E2 at controlled dose for 200 to 400 days (Hsieh 1987; Chien 1992). 
The release of drug dispersing in a matrix environment is based on the hypothesis that the 
drug particles cannot move from their individual positions in the polymer matrix. The drug 
solids in the layer closer to the surface of the device are first diffused, so that this layer 
becomes a drug depletion zone. Then, the drug particles in the next layer begin to dissolve 
and diffuse, resulting in the growing thickness of drug depletion layer. This thickness 
becomes greater and greater as more drug solids are eluted out of the device, leading to 
inward advancement of the interface of drug dispersion zone/ drug depletion zone into the 
core of the device for another thickness൫݀ℎ௣൯. Therefore, the rate of drug release from the 
polymer matrix diffusion-controlled drug delivery system is time-dependent and 
www.intechopen.com
Solid State and Thermal Behavior of  
17-Estradiol in Ammonioethyl Methacrylate Ester Copolymer 409 
progressively decreases in response to increase in the thickness of the diffusional path as time 
goes by. At steady state the rate of drug release ቀௗொௗ௧ቁ is defined as followed (Chien 1992); 
 ௗொௗ௧ = ቀ஺஼೛஽೛ଶ௧ ቁభమ (10) 
where A is the initial drug loading dose in the polymer matrix, Cp is the drug solubility in 
the polymer, which is also the drug reservoir concentration in the system, and Dp is the 
diffusivity of the drug molecules in the polymer matrix.  
Integration of Equation (10) gives the relationship of the cumulative amount of drug release 
(Q) directly varied with the square root of time as the following equation; 
 ܳ = ൫ʹܣܥ௣ܦ௣൯భమሺݐሻభమ (11) 
From Equation (11), the cumulative amount of drug released from the polymer matrix 
diffusion-controlled drug delivery system is controlled by the loading dose, solubility and 
diffusivity of the drug in the polymer matrix. This confirms that the drug solubility in the 
polymer is also one of significant factors affecting the amount of drug released from this 
delivery system. 
One major drawback of the polymer matrix diffusion-controlled drug delivery system is its 
inability to achieve a constant release due to the variable thickness of the drug depletion 
zone. The thickness of the drug depletion zone increases as the release of drug proceeds. 
Therefore, the rate of drug release decreases with the reciprocal of the square root of time. 
Rippe and Johnso (Rippie 1969), Cobby et al. (Cobby 1974), and Hsieh et al. (Hsieh 1983) 
revealed that the shape of a matrix could be a factor affecting drug release, so that several 
researches since last 2 decades have been done in development of new designs of matrix 
system in order to achieve the zero-order or near zero-order release kinetics. 
3.2.1 Hemipheric polymer matrix diffusion-controlled drug release 
Drug released from hemispheric polymer matrix device has been designed to achieve a 
constant release (Hsieh 1983). The device is composed of the drug dispersing in a 
hemispheric polymer matrix, coated with an impermeable material except for a small cavity 
cut into the center of the flat surface as shown in Figure 1.  Only a cavity in the center where 
 
 
Fig. 1. Diagram of a hemispheric polymer matrix device: ai was the inner radius; ao was the 
outer radius; R was the distance to the interface between the drug depletion zone (white 
area) and the drug dispersing zone (diagonal lines); and black represented coated regions 
through which the drug release could not occur (From Hsieh, et. al., 1983). 
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the drug can be released the interface between drug depletion zone and drug dispersing 
zone moves into the interior as a front. The inwardly-releasing hemisphere increases the 
available area, where the drug can be released, so as to compensate the increase in diffusion 
distance of drug transport. 
The rate of drug release ቀௗொௗ௧ቁ from the hemispheric polymer matrix device can be expressed 
as (Hsieh 1983); 
 ௗொௗ௧ = ʹߨܥ௦ܦ௣ܽ௜ ቀ ோோି௔೔ቁ (12) 
where π is a constant value, Cs is drug solubility in the surrounding medium, Dp is the 
diffusivity of drug molecules in the polymer matrix, ai is radius of the cavity, and R is radial 
distance to interface between drug depletion zone and drug dispersing zone within the 
matrix. 
Since R-ai becomes equal to R when R » ai. Equation (12), then, can be simplified to; 
 ௗொௗ௧ = ʹߨܥ௦ܦ௣ܽ௜ (13) 
Each of the terms in Equation (13) is a constant. Thus, the rate of drug released from the 
hemispheric polymeric matrix device with small ai is essentially constant. The theoretical 
analysis has been agreed with the experimental data obtained from Hsieh et al. (Hsieh 1983). 
Their study addressed that hemispheric matrices acted as constant release systems for both 
sodium salicylate and bovine serum albumin, which were represented as small molecule 
and macromolecule, respectively. 
3.2.2 A hollow cylindrical polymer matrix diffusion-controlled drug release 
Drug released from a hollow cylindrical matrix device demonstrates a constant release profile 
because mechanism of drug released from this device is almost similar to that of the 
hemispheric polymer matrix device. This device has been fabricated by Vandelli and 
Cameroni since 1993 (Vandelli 1993a; Vandelli 1993b). It is a cylindrical polymer-drug matrix 
with a hole bored in the center of the flat surface through both sides of the matrix as displayed 
in Figure 2. All surfaces of the device are coated with an impermeable polymer except a central 
hole where the drug can be released, similar to the hemispheric polymer matrix device. 
 
 
Fig. 2. Diagram of a hollow cylindrical matrix device: ai was the inner radius; ao was the outer 
radius; R is the distance to the interface between the drug depletion zone (light gray area) and 
the drug dispersing zone (dark gray area); and black representing coated regions through 
which the drug release could not take place (Reproduced from Wiranidchapong, 2006). 
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In addition, the swelling polymer used in the matrix can modulate the drug release 
following pseudo-zero order kinetics regardless of the loaded drug. This device regulates 
the drug release by swelling process and the effect of matrix geometry (Vandelli 1993b). 
3.2.3 The three-layer polymer matrix diffusion-controlled drug release 
The three-layer polymer matrix device has been designed to achieve zero-order kinetics of 
the drug release under the trade name of Geometrix Technology since 1992 (Conte 1993; 
Conte 1996; Conte 2000; Abdul 2004). In fact, this device is a multi-layer tablet, which 
comprises of a matrix core containing an active drug and one or more barriers applied to the 
core directly during the tableting process. The barriers reduce the burst release of the drug 
in the core by limiting the available surface for the drug release and controlling the solvent 
penetration rate at the same time. During the subsequent portions of the barriers dissolve, 
the erosion of these swollen barriers is dominated and the surface available for the drug 
release slowly increases. In this way the decrease of delivery rate due to the increase of 
diffusion path-length, corresponding to the increase of drug depletion zone, is 
counterbalanced by the simultaneous increase of the available area for drug release. Thus, 
the drug release can be maintained at a relatively constant level during the swelling and 
erosion of the barriers.  
Maggi et al. (Maggi 2000) declared that release profiles of the three-layer matrices with the 
same cores and different barriers were different. The barriers containing polymers of higher 
viscosity were stronger reduction in the rate of drug release than those containing polymers 
of lower viscosity. In the same way, the cores containing the polymers of higher viscosity 
released the drug at a lower rate than those containing the polymers of lower viscosity. 
However, the dissolution profiles of the three-layer systems with the same barriers but 
different polymers used in the cores were similar. Their work was focused on the 
modulation of highly water-soluble drug released such as diltiazem hydrochloride. 
Therefore, the core had less effect on the modulation of drug release while the barriers 
played the leading role in controlling drug release from the three-layer matrix system used a 
highly water-soluble drug as a model drug. 
The three-layer polymer matrix containing 17-estradiol (E2) as a model drug was 
produced by Wiranidchapong (Wiranidchapong 2006). E2 dispersing in poly(ethyl 
acrylate-methyl methacrylate-trimethylammonioethyl methacrylate chloride) 1:2:0.1 or 
Eudragit® RS (ERS) at weight percent of 10, 20, and 30 was used in the core component 
while ERS free drug was used as polymeric barriers on both sides of the core. In vitro 
release of E2 from the three-layer matrices exhibited 80 % of cumulative amount of E2 
released within 7 days in all cases as shown in Figure 3(a). E2 daily release rate from these 
matrices is shown in Figure 3(b). The increase in weight percent of E2 in the core did not 
significantly increase E2 daily release rate.  
To compare E2 release profiles obtained from the three-layer matrices containing different 
weight percents of E2 used in the cores, the similarity factor (f2) was used in the assessment. 
The f2 test adopted by the Center for Drug Evaluation and Research (FDA) and by Human 
Medicines Evaluation Unit of the European Agency for the Evaluation of Medicine Products 
(EMEA) can be defined as the following equation (Costa 2001). 
 ଶ݂ = 5Ͳ × ݈݋݃ ൤ቄͳ + ቀଵ௡ቁ∑ ห ௝ܴ − ௝ܶหଶ௡௝ୀଵ ቅି଴.ହ × ͳͲͲ൨ (14) 
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where n is the sampling number, Rj and Tj are the percent dissolved of two comparative 
formulations at each time point j. FDA and EMEA have suggested that two dissolution 
profiles are declared similar if f2 is between 50 and 100. The higher f2 value, the more similar 
dissolution profiles are obtained (Costa 2001). 
 
 
Fig. 3. In vitro release (A) and the daily rate (B) of E2 released from the three-layer matrices 
containing 10, 20, and 30 % w/w E2 in ERS used in the cores (Reproduced from 
Wiranidchapong, 2006). 
f2 values of E2 release profiles of the core containing 10 % w/w E2 compared with those 
containing 20 and 30 % w/w E2 were 57.18 and 58.16, respectively. In addition, f2 values 
obtained from the comparison of E2 release profiles of the core containing 20 % w/w E2 with 
those containing 30 % w/w E2 was 77.77 (Wiranidchapong 2006). Thus, E2 release profiles of 
the three-later polymer matrices containing 10, 20, and 30 % w/w E2 in ERS used in the 
cores were similar.  
In the case of the increase in weight percent of drug in the matrix, the porosity upon drug 
depletion is increased and the tortuosity is reduced, so that rate of drug release should 
increase. However, the rate of E2 release did not increase as weight percent of E2 in the cores 
increased. This suggested that the increase in porosity and the decrease in tortuosity in the 
core of the three-layer matrix could not elevate the E2 release rate. The porosity and the 
tortuosity might not be the important factors in controlling E2 release from this system. 
Similar study was investigated with norethindrone (NET), the other poorly water-soluble 
drug, used in the core and ERS employed as barriers of the three-layer matrix 
(Wiranidchapong 2006). The cumulative release and the daily release rate of NET from the 
three-layer matrices containing 30, 40, and 50 % w/w NET in ERS used in the cores are 
shown in Figure 4. NET release profiles showed 80 % of NET released within 14 days in all 
cases. NET daily release rate exhibited relatively constant within 9 days. 
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Fig. 4. In vitro release (A) and the daily rate (B) of NET released from the three-layer 
matrices containing 30, 40, and 50 % w/w NET in ERS used in the cores (Reproduced from 
Wiranidchapong, 2006). 
From preliminary study conducted at 37°C, 120 rpm, the solubility of E2 and NET in 3.5 % 
w/v benzalkonium chloride in phosphate buffer pH 7.4 used as release medium were 891.29 
μg/ml and 460.16 μg/ml, respectively. The solubility of NET in the release medium is 
around two times lower than that of E2 corresponding to two times longer extended release 
of NET than that of E2. 
The f2 values obtained from the comparison of NET release profile of the three-layer matrix 
in which core containing 30 % w/w NET with those containing 40 and 50 % w/w NET were 
73.23 and 72.55, respectively. Furthermore, f2 values obtained from NET release profile of the 
core containing 40 % w/w NET compared with that of 50 % w/w NET was 96.69. This 
indicated the similarity among NET release profiles obtained from the three-layer polymer 
matrices containing 30, 40, and 50 % w/w NET in the polymeric cores. 
This study represented that the intrinsic solubility of E2 and NET affected the duration of 
drug released from the three-layer matrix. The increase in weight percent of E2 and NET 
used in the core corresponding to the increase of the porosity and decrease of the tortuosity 
did not increase the daily release rate. The solubility of E2 and NET in the release medium 
predominated in controlling the E2 and NET release when compared with the porosity and 
the tortuosity upon drug depletion. 
Further study was to investigate the effect of the barrier and the type of polymer used in the 
core and barrier on NET released from the three-layer matrix (Wiranidchapong 2006). 
Poly(ethyl acrylate-methyl methacrylate-trimethylammonioethyl methacrylate chloride) 
1:2:0.1 and 1:2:0.2 or Eudragit® RS (ERS) and Eudragit® RL (ERL), respectively have been 
used as rate controlling polymers. ERL is more permeable than ERS because of higher 
content of quaternary ammonium groups in the structure. The NET released profile 
obtained from the three-layer matrix using ERL in the core was compared with that of ERS. 
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In addition, the NET released profiles obtained from the three-layer matrices having the 
same cores but different kinds of polymer used in the barriers and without the barriers were 
also investigated. The percentage of drug loading was set at 30. 
The cumulative release of NET from the three-layer matrices using ERL in the cores with 
barrier layers of either ERL or ERS exhibited 80 % of NET released within 2 days whereas 
those of ERS in the cores with either ERS or ERL in the barriers and without the barriers 
exhibited 80 % of NET release within 14 days as illustrated in Figure 5. The difference of 
polymer used in the core significantly changed NET release profile but the difference of 
polymer used in the barriers, including without the barriers did not significantly change 
NET release profile. Therefore, the core exerted more influence on the modulation of a 
poorly water-soluble drug release than the barrier did.      
NET release profiles of the devices containing ERS in the cores were compared with each 
other. The f2 values of NET release profiles obtained from the device using ERS in the barriers 
compared with those of ERL and without the barriers were 75.36 and 77.76, respectively. In 
addition, f2 value of NET release profile obtained from the device using ERL in the barriers 
compared with that of without barriers was 86.00. The NET release profiles obtained from the 
devices using ERS in the cores with the barriers using either ERS or ERL and without the 
barriers were similar. Thus, the three-layer design did not affect the NET release. 
 
 
Fig. 5. In vitro release of NET from the three-layer matrices containing ERS or ERL used in 
the cores and ERS or ERL used in the barriers, including without the barriers (Reproduced 
from Wiranidchapong, 2006). 
Approximately 60 % of either E2 or NET released from the three-layer matrices investigated 
in this study were well fitted with the zero-order released model by linear regression 
analysis. The coefficient of determination (R2) obtained from each fit was in the range of 
0.9946 – 0.9999 (Wiranidchapong 2006). The zero-order model was apparently appropriate 
to describe either E2 or NET released from the matrices using ERS as the rate-controlling 
polymer. As previously mentioned, the zero-order kinetic of drug released is accomplished 
in the polymer membrane permeation-controlled drug delivery system in both conditions 
www.intechopen.com
Solid State and Thermal Behavior of  
17-Estradiol in Ammonioethyl Methacrylate Ester Copolymer 415 
governed by the polymeric membrane-modulated permeation process and the diffusion 
layer-limiting partition-controlled process. In case of incompletely coated membrane such as 
the three-layer polymeric matrix, the hydrodynamic diffusion layer (hd) predominates in 
controlling the drug release. As seen in Equation (9), the rate of drug release is a result of 
drug solubility in the surrounding medium. 
Chandrasekaran and Paul (Chandrasekaran 1982) announced that the solubility of poorly 
water-soluble drug predominated and offered as the limiting resistance to drug release. This 
resulted in the saturated concentration of dissolved drug at the inside of matrix pores when 
drug loading exceeded the drug solubility under the given condition. Non-dissolved drug 
was not available for diffusion but it acted as a drug reservoir for keeping constant the 
absolute amount of drug release within a certain period of time. The zero-order release 
kinetic could be achieved under this condition (Siepmann 2001). Furthermore, Kim (Kim 
2000) indicated that the geometry was not an important factor for a drug dissolution 
controlled release system and the increase in the porosity and the reduction in the tortuosity 
did not influence the kinetics of drug release. Therefore, the zero-order kinetic of either E2 or 
NET released from the matrices was a result of the inherent solubility of E2 and NET 
providing the drug dissolution controlled release system (Wiranidchapong 2006). 
The E2 released from the polymeric matrix is controlled by the dissolution of E2 in the 
surrounding medium. Therefore, an alteration in the solid state of E2 dispersing in the 
polymer matrix can modify the characteristic of E2 release. Solid state of E2 should be 
revealed in both cases of pure drug and the drug dispersing in the polymer under various 
conditions, which might be appeared in the manufacturing process. 
4. Solid state properties of estradiol 
The most common form of E2 is the hemihydrates (Variankaval 2000; Wiranidchapong 2008). 
However, E2 can exist in various kinds of pseudopolymorphs as hemisolvates, dependent 
on the type of solvent used in the crystallization. For an example, E2-hemisolvate of 
methanol was produced by crystallization in saturated solution of E2 in methanol 
(Variankaval 2000). In addition, either polymorphs or pseudopolymorphs exhibit the 
definite arrangement of molecules inside the crystal lattice. This directly affects on a crystal 
habit, which is an external shape of the crystal. Thus, crystal morphology is a specific 
characteristic for each polymorphic form. An alteration in polymorphic state possibly 
changes the crystal habit and/or even crystal morphology, leading to significant variation in 
raw-material characteristics such as particle orientation, flowability, packing, compaction, 
suspension stability and dissolution. This can lead to serious implications of physical 
stability in dosage forms (Niazi 2007). 
E2 can exist in the amorphous form and at least three crystalline forms, including E2-
hemihydrate (Variankaval 2000; Wiranidchapong 2006; Wiranidchapong 2008). Differential 
scanning calorimetry (DSC)  curve reveals that the three crystal forms and amorphous form 
of E2 are inter-convertible under various thermal conditions as displayed in Figure 6(A) 
(Wiranidchapong 2006; Wiranidchapong 2008). This indicates that the polymorphic 
transformation of E2 possibly occurs during manufacturing process in which optimal 
thermal energy has been utilized. Thus, inconsistency of E2 polymorphs have probably been 
found in pharmaceutical products obtained from inadequate quality control of 
manufacturing procedures. Different polymorphs exhibit dramatic change in physical and 
chemical properties. This leads to inconsistency in dissolution rate, rate of drug release from 
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controlled-release product, and bioavailability. To control the product quality, 
physicochemical properties of E2 polymorphs should be verified. 
4.1 Characterization by DSC and TGA   
From DSC analysis, E2-hemihydrate exhibited the melting point onset at 179.2 C 
corresponding to the third endotherm observed in the first heating run (DSC; 0-182 C at 10 
K/min). The first endotherm (onset at 110 C) and second endotherm (onset at 174 C) in the 
first heating run corresponded to the partial release of hydrogen bonded water and the 
complete loss of water lattice, respectively. The water loss observed in the first scan was 
agreed with a weight loss of 3.2 % of E2 measured by thermogravimetric analysis (TGA) as 
illustrated in Figure 6(B) (Wiranidchapong 2006; Wiranidchapong 2008). This result 
indicated that the stoichiometry of E2 should be C18H24O2. 12 H2O. 
 
Fig. 6. (A) DSC curve of E2 scanned with the program: (1) heating to 182 C, 10 K/min, 
cooling to 0 C, 20 K/min, and then (2) heating to 250 C, 10 K/min; (B) TGA of E2 
(Reproduced from Wiranidchapong, 2008). 
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On cooling (DSC; 182-0 C at 20 K/min) the glass transition temperature (Tg) was observed 
around 84.2 C, correlating to that observed in the second heating (DSC; 0-250 C at 10 
K/min). This aspect revealed an appearance of amorphous E2 after E2-hemihydrate had 
been melted and then rapidly cooled. In the second heating the amorphous E2 in glassy state 
was changed to that in rubbery state when the temperature reached the Tg, followed by 
recrystallization into ED form as stated by Variankaval et al. (Variankaval 2000) and 
anhydrous E2 exhibiting their melting points at 169.6 C and 179.2 C, respectively 
(Variankaval 2000; Wiranidchapong 2006; Wiranidchapong 2008). 
4.2 Characterization by X-ray powder diffraction  
Each polymorph of E2 exhibits the definite X-ray powder diffraction (XRPD) patterns as 
illustrated in Figure 7. E2-hemihydrate demonstrates characteristic peaks at 13.14, 15.74, 
18.26, 22.62, and 26.58° (Latsch 2003; Park 2005; Wiranidchapong 2006; Wiranidchapong 
2008). Anhydrous E2 prepared by heating E2-hemihydrate from 0-175 °C and 0-180.5 °C at 
heating rate of 5 K/min exhibited the characteristic peaks at 13.60, 16.78, 21.00, and 24.72°, 
which were not observed in the diffraction pattern of E2-hemihydrate. 
 
 
Fig. 7. XRPD of E2-hemihydrate (A); anhydrous E2 produced from either heating to 175 C, 5 
K/min (B); or heating to 180.5 C, 5 K/min (C); and ED form of E2 (D) (Reproduced from 
Wiranidchapong, 2008). 
The relative peak intensity of anhydrous E2 obtained from heating to 180.5 °C was less than 
that of anhydrous E2 obtained from heating to 175 °C. In addition, the diffraction peaks of 
anhydrous E2 obtained from heating to 180.5 °C did not significantly separate from baseline, 
indicating a mixture of crystalline form and amorphous form. This represents the 
inconsistency in the appearance of E2 polymorph when the process slightly changes. ED 
form of E2 prepared by heating E2-hemihydrate to 180.5 °C at 5 K/min and cooling to 0 °C at 
20 K/min and finally heating to 140 °C at 5 K/min manifested the definite diffraction 
pattern, which exhibited the characteristic peaks at 12.64 and 19.94°. This feature indicates 
that XRPD analysis can be used to investigate polymorphic forms of E2, which are inter-
convertible under various thermal conditions. 
4.3 Characterization by FTIR 
FTIR spectra of E2-hemihydrate, anhydrous E2, and the mixture of anhydrous E2 with 
amorphous E2 are displayed in Figure 8. E2-hemihydrate exhibited very broad bands 
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centered at 3435.95 and 3232.06 cm-1 attributed to O-H stretching of hydroxyl group adjacent 
to C-17 and C-3 positions in E2 chemical structure, respectively (Barnett 1995; 
Wiranidchapong 2006; Wiranidchapong 2008; Wiranidchapong 2009). The broad band 




Fig. 8. FTIR spectra of E2-hemihydrate (A); anhydrous E2 (B); and the mixture of anhydrous 
E2 with amorphous E2 (C), recorded at room temperature in the range of 3800-2600 cm-1 
(left) and 1800-900 cm-1 (right). 
Anhydrous E2 prepared by heating E2-hemihydrate to 175 °C at 5 K/min displayed the peak 
around 3530 cm-1 in the FTIR spectrum. This peak corresponded to free hydroxyl group 
absorption (Kuo 2001a; Kuo 2001b; Wiranidchapong 2006; Wiranidchapong 2008; 
Wiranidchapong 2009). The appearance of this peak was agreed with the water loss during 
heating. However, broad bands centered at 3434.27 and 3245.29 cm-1 attributed to O-H 
stretching of hydroxyl group adjacent to C-17 and C-3 positions respectively in the E2 
chemical structure, were still observed. 
For FTIR spectrum of E2 heated to 220 C at 5 K/min, which was presumably the mixture of 
anhydrous E2 with amorphous E2, the O-H stretching bands of hydroxyl groups adjacent to 
the C-17 and C-3 positions and C-H stretching vibration of aromatic ring in the regions of 
3100-3000 cm-1 (Silverstein 1991) shifted to lower wavenumber when compared with those 
of E2-hemihydrate and anhydrous E2. Furthermore, three consecutive peaks in the range of 
1655-1580 cm-1 attributed to absorption of the mixtures of tautomeric keto and enol forms 
(Silverstein 1991) were noticed in FTIR spectrum of E2 heated to 220 C whereas only two 
consecutive peaks in this region were observed in FTIR spectra of E2-hemihydrate and 
anhydrous E2. Due to the absorption peak in this region affected by physical state, electronic 
and mass effects of neighboring substitutes, conjugation, hydrogen bonding, and ring strain 
(Silverstein 1991), this might be the characteristics of amorphous E2 blended with anhydrous 
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E2. In addition, the peaks in the regions of 1300-900 cm-1 illustrated different shapes from 
those of E2-hemihydrate, and anhydrous E2. 
According to drug dissolution and drug solubility in the polymer affecting the rate of drug 
released from either polymer membrane permeation- or polymer matrix diffusion-
controlled release systems, solid state of E2 dispersing in the polymer should also influence 
on the rate of E2 release. Solid dispersion prepared by solvent evaporation is generally used 
to distribute drug into the polymeric matrix (Serajuddin 1999). Solid dispersions containing 
E2 in ERS at 1 and 2 % w/w exhibited amorphous state of E2 in the dispersion while those 
containing E2 at 10, 20, and 30 % w/w illustrated crystalline state of E2 in the dispersion 
(Wiranidchapong 2006). This interpretation was supported by photomicrographs of ERS, 
solid dispersion containing 1, 2, 10, 20, and 30 % w/w of E2 in ERS and E2 under polarized 
light microscope as shown in Figure 9. The absence of birefringence was observed in ERS 
and solid dispersions containing 1 and 2 % w/w of E2. This is a characteristic of amorphous 
substance, which cannot turn plane polarized light and cannot reflect purple light to other 
wavelengths of visible lights. On the other hand, the birefringence was observed in solid 
dispersions containing 10, 20, and 30 % w/w of E2 and E2 crystal powder. This is a 
characteristic of crystalline substance, which is able to turn plane polarized light and reflect 
purple light to other visible wavelengths. 
 
 
Fig. 9. Photomicrographs obtained from polarized light microscope: (A) ERS; solid 
dispersions containing E2 in ERS at weight percent of (B) 1; (C) 2; (D) 10; (E) 20; (F) 30; and 
(G) E2-hemihydrate (Reproduced from Wiranidchapong, 2006). 
To compare with approximately 80 % of the E2 released from the matrices containing E2 at 
10, 20, and 30 % w/w in the dispersion within 7 days, the matrices, which were composed of 
E2 at 1 and 2 % w/w in the dispersions released approximately 60-80 % of the E2 within 3 
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days (Wiranidchapong 2006). This study was in accordance with the finding of amorphous 
E2 in the dispersion containing E2 at 1 and 2 % w/w. Amorphous state is 
thermodynamically unstable. The molecular interactions of amorphous substance are 
weakened and usually gone into breaking. Therefore, amorphous E2 exhibited higher 
dissolution rate than crystalline E2, so that the rate of E2 release from matrix containing 
amorphous E2 is higher than that of the matrix containing crystalline E2. 
The polymorphic state of E2 in the polymer matrix can be observed not only by polarized 
light microscope but also by DSC and/or MTDSC (modulated temperature differential 
scanning calorimetry) (Wiranidchapong 2006; Wiranidchapong 2008; Wiranidchapong 
2009). To understand how DSC and/or MTDSC can differentiate between amorphous state 
and crystalline state of E2 dispersing in the polymer matrix. Thermal behavior of solid 
dispersion containing E2 in ERS should be explored. 
5. Thermal behavior of E2 in ERS solid dispersion 
In general, Tg is one of thermal properties of an amorphous material observed by thermal 
analysis. Likewise, the melting point is a thermal property of a crystalline material.  In the 
case of the amorphous E2 existing in the polymer matrix, either E2 or polymer in the matrix 
are amorphous materials. Thus, both amorphous E2 and the polymer can manifest their Tg. 
A question is how the Tg behavior of this solid dispersion is. Which one between a single Tg 
or both Tg of amorphous E2 and the polymer should be observed? For a solid dispersion 
composed of crystalline E2 in the polymer matrix, what the temperature should be the 
melting point of E2 in the dispersion? Does the polymer influence on the melting point of E2? 
To understand the thermal behaviors of E2 in ERS solid dispersion, the theory of the 
miscibility between the binary mixtures in which a polymer blend should be addressed. 
5.1 Tg behavior described by the Gordon Taylor equation 
In polymer sciences, the miscibility of a polymer blend composed of two amorphous 
polymers can be determined by thermal analysis. A single Tg point is an indication of full 
miscibility of a polymer blend (Kuo 2001a; Kuo 2001b; Maldonado-Santoyo 2004). On the 
contrary, an immiscible polymer blend exhibits more than one Tg representing Tg of 
amorphous pure polymers used as components (Kuo 2001a). In general, Tg of a miscible 
blend lies between Tg of the pure polymers, which can be predicted by Gordon-Taylor 
equation or its modified version equation (Maldonado-Santoyo 2004). Either Tg or weight 
fraction of binary polymer components are major factors in predicting the Tg of a miscible 
polymer blend by Gordon-Taylor equation and its modified version equation. 
Gordon-Taylor equation has been proposed for the composition dependence on the Tg of 
miscible polymer blends derived under these assumptions (Schneider 1988); 
1. The contacts due to the interaction between the components of the blend are 
responsible for conformational arrangement, free volume distribution, and 
conformational energy barriers. 
2. The probabilities of binary contact are related to the volume fractions of the 
components, so that the composition dependence on the Tg has been related to the 
volume fractions (Ø) of the components. 
The Gordon-Taylor equation with respect to the volume fraction (Ø2) of the stiffer polymer 
component (with Tg2) has been defined as the following relationship (Schneider 1988); 
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 ೒்ି ೒்భ೒்మି ೒்భ = ሺͳ + ܭଵሻ∅ଶ − ሺܭଵ + ܭଶሻ∅ଶଶ + ܭଶ∅ଶଷ (15) 
The parameters K1 and K2 are related to the difference of the Tg of the polymer components ൫ ௚ܶଶ − ௚ܶଵ൯, so that 
 ܭଵ = ௄భ∗൫ ೒்మି ೒்భ൯ (16) 
and 
 ܭଶ = ௄మ∗൫ ೒்మି ೒்భ൯ (17) 
The system-specific constant ܭଵ∗ is related to the interaction energy differences between 
hetero- and homo-contacts, whereas ܭଶ∗ considers the energetic effects on the binary contacts 
of the molecular surrounding. 
The ideal behavior of the polymer blend exhibits the equality of the different energetic 
effects. This means the identical energetic effects of both hetero- and homo-contacts and the 
equality of the contact energy of the molecular neighborhood. So both ܭଵ∗ and ܭଶ∗ are equal 
to zero in the idealized condition of the Tg behavior of miscible polymer blend. The Gordon-
Taylor equation resulted from the idealized condition can be expressed; 
 ೒்ି ೒்భ೒்మି ೒்భ = ∅ଶ (18) 
 ௚ܶ = ∅ଶ ௚ܶଶ + ሺͳ − ∅ଶሻ ௚ܶଵ (19) 
Because of ∅ଵ + ∅ଶ = ͳ, and then 
 ௚ܶ = ∅ଶ ௚ܶଶ + ∅ଵ ௚ܶଵ (20) 
To express in term of the temperature-dependent weight fraction ሺݓ௜ሻ, the volume fractions ሺ∅௜ሻ are given by the expression; 
 ∅௜ = ሺ∆ఈ೔×௪೔ሻ ఘ೔⁄∑ ሼሺ∆ఈ೔×௪೔ሻ ఘ೔⁄ ሽ೔  (21) 
where ߩ௜ is the density of the components and ∆ߙ௜ is the difference between the expansion 
coefficients of the melt (L) and the glass (gl) at Tgi ൫∆ߙ௜ = ߙ௅,௜ − ߙ௚௟,௜൯. 
Introducing Equation (21) into Equation (20), yielding the Gordon-Taylor equation 
expressed in term of the temperature-dependent weight fraction as displayed; 
 ௚ܶ = ఘమ∆ఈభ௪భ ೒்భାఘభ∆ఈమ௪మ ೒்మሺఘమ∆ఈభ௪భାఘభ∆ఈమ௪మሻ  (22) 
Due to ܭ = ఘభ∆ఈమఘమ∆ఈభ, so that Equation (22) can be rearranged as; 
 ௚ܶ = ௪భ ೒்భା௄௪మ ೒்మ௪భା௄௪మ  (23) 
In the case of polymer blends exhibiting the behavior deviating from the ideal behavior, the 
fit of Gordon-Taylor equation to experimental data fails. This suggests an interaction 
contribution to the Gordon-Taylor parameters (K). The Kwei equation is recommended in 
this case. The Kwei relation is identical to a second-order equation of the proposed model 
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expressed in Equation (15). It considers different energetic effects of the binary contact (K1 ≠ 
0), but neglects the effects of the immediate neighborhood of contacts (K2 = 0). Therefore, 
Equation (15) can be written under this assumption as shown; 
 ೒்ି ೒்భ೒்మି ೒்భ = ሺͳ + ܭଵሻ∅ଶ − ܭଵ∅ଶଶ (24) 
Equation (24) can be illustrated in term of the corrected weight fraction ሺݓ௜௖ሻ as the 
following equations; 
 ೒்ି ೒்భ೒்మି ೒்భ = ሺͳ + ܭଵሻݓଶ௖ − ܭଵݓଶ௖ଶ  (25) 
 ௚ܶ = ݓଵ௖ ௚ܶଵ +ݓଶ௖ ௚ܶଶ + ൫ ௚ܶଶ − ௚ܶଵ൯ሺܭଵݓଶ௖ݓଵ௖ሻ (26) 
Due to ݓଵ௖ = ݓଵ ሺݓଵ + ܭݓଶሻ⁄  and ݓଶ௖ = ܭݓଶ ሺݓଵ + ܭݓଶሻ⁄ , so that Equation (26) can be 
rewritten as displayed; 
 ௚ܶ = ௪భ ೒்భା௄௪మ ೒்మ௪భା௄௪మ + ൫ ௚ܶଶ − ௚ܶଵ൯ ௄భ௄௪మ௪భሺ௪భା௄௪మሻమ (27) 
Because of ݍ = ൫ ௚ܶଶ − ௚ܶଵ൯ ௄భ௄ሺ௪భା௄௪మሻమ, then Equation (27) can be illustrated as; 
 ௚ܶ = ௪భ ೒்భା௄௪మ ೒்మ௪భା௄௪మ + ݍݓଶݓଵ (28) 
Equation (28) is the Kwei equation, which is the second order equation of the proposed 
model. The q parameter reflects the balance between breaking the intra bonding and 
forming the inter bonding. Normally the q parameter corresponds to the strength of 
hydrogen bonding. The q value of the polymer blend should depend on an entropy change 
corresponding to the change in the number of hydrogen bonding interactions. In the case of 
negative q value, it indicates that the self-associated hydrogen bonding is stronger than the 
inter-associated hydrogen bonding. In reciprocal way, the positive q value indicates that the 
self-associated hydrogen bonding is weaker than the inter-associated hydrogen bonding. 
The higher q value, the stronger hydrogen bonding (Kuo 2001a; Kuo 2001b). 
The third order equation of the proposed model considers the contact interaction energies 
(K1 ≠ 0) and the influence of the molecular neighborhood on the contact energy (K2 ≠ 0), so 
that Equation (15) can be written in the term of the corrected weight fraction of the stiffer 
polymer ሺݓଶ௖ሻ as displayed below; 
 ೒்ି ೒்భ೒்మି ೒்భ = ሺͳ + ܭଵሻݓଶ௖ − ሺܭଵ + ܭଶሻݓଶ௖ଶ + ܭଶݓଶ௖ଷ  (29) 
The Equation (29) can be resolved for the Tg of the blend as the following expression; 
 ௚ܶ = ሺଵି௪మሻ ೒்భା௄௪మ ೒்మଵାሺ௄ିଵሻ௪మ + ௄భ∗௄ሼଵାሺ௄ିଵሻ௪మሽమ × ሺͳ − ݓଶሻݓଶ − ି௄మ∗௄మሼଵାሺ௄ିଵሻ௪మሽయ × ሺͳ − ݓଶሻݓଶଶ (30) 
Equation (30) is an extended Gordon-Taylor equation, which is written in term of the weight 
fraction of the stiffer polymer ሺݓଶሻ. Due to Equations (16) and (17), ܭଵ∗ and ܭଶ∗ are related to 
K1 and K2, respectively, so that the influence of the weight fraction of the components on the 
Tg is included both K1 and K2. 
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The application of Gordon-Taylor equation and its modified version equation has been 
extended to describe the Tg behavior of E2 in ERS solid dispersion (Wiranidchapong 2006; 
Wiranidchapong 2008; Wiranidchapong 2009). The study revealed that solid dispersions 
containing E2 in ERS at weight percent of 1-90 manifested a single Tg lying between the Tg of 
ERS (66.21 °C) and E2 (83.77 °C) as displayed in Figure 10. 
 
 
Fig. 10. Tg of E2 in ERS solid dispersions at concentration range of 0-100 % w/w investigated 
by MTDSC with the program: heating to 182 C, 10 K/min, cooling to 25 C, 20 K/min, an 
isothermal period for 5 min at 25 C, and finally heating to 250 C, 5 K/min (Reproduced 
from Wiranidchapong, 2008). 
In addition, the Tg shifted toward the Tg of E2 when weight fractions of E2 in the dispersions 
increased. This behavior was observed in E2 in ERS solid dispersions investigated by 
MTDSC with the program of heating from 25 to 182 °C at 10 °C/min, cooling to 25 °C at 20 
°C/min, an isothermal period for 5 min at 25 °C, and finally heating to 250°C at 5 °C/min. 
This heating program provided the transformation of E2-hemihydrate into amorphous E2 
blended with ERS as the same as a blend of amorphous polymers. Thus, the Tg behavior of 
these blends could be described by the principle of Gordon-Taylor equation. However, the 
experimental Tg values were better fitted to Kwei equation than the Gordon-Taylor 
equation. The q value, the Kwei equation parameters, obtained from the curve-fitting was 
not equal to zero, which implied an interaction between E2 and ERS in the blend. 
5.2 The melting point behavior described by the flory-huggins theory 
In the case of a crystalline polymer blended with an amorphous polymer, the melting point 
depression of a crystalline polymer in blend indicates the miscibility and interaction between 
the polymer components. Partially miscible or immiscible blends do not typically show the 
depression of melting point whereas a miscible blend displays the melting point depression 
when the content of amorphous polymer increases. The temperature reduction was a result of 
morphological effects and thermodynamic reasons (Kuo 2001a; Kuo 2001b). In a 
thermodynamically miscible blend, an amorphous polymer resides inside the interlamellar 
regions of a semi-crystalline polymer. It expands the interlamellar regions. The spherulite 
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radial growth rate, time to half volume crystallization and melting temperature of semi-
crystalline component generally decrease as the concentration of the amorphous polymer 
increases. The mean field self-consistent theory used to a model of a blend containing di-block 
copolymers composing of crystallisable and amorphous copolymer blocks has been proposed. 
The free energy based on this theory can be expressed as a sum of free energy of free 
crystalline and amorphous blocks, entropy and enthalpy of interactions between these two 
blocks. For long chain polymers, the effect of the end groups can be ignored. The change in 
partial free energy of the crystals in a miscible blend ሺ∆݃ଶ௕ሻ can be expressed (Rostami 2000); 
 ∆݃ଶ௕ = ∆݃ଶ + ∆݃௠ (31) 
where ∆݃ଶ is the change in partial free energy of crystalline unit of a homopolymer and ∆݃௠ 
is the change in partial free energy of the mixture. 
The equilibrium melting temperature is defined as the last temperature that infinitely long 
crystal melts. By definition, at the equilibrium melting temperature of the blends, where the 
last crystal melts, ∆݃ଶ௕ becomes zero, so that Equation (31) can be expressed as following 
equations; 
 ∆݃ଶ = −∆݃௠ (32) 
 ∆ℎଶ − ௠ܶ௕∆ܵଶ = −∆݃௠ (33) 
 ͳ − ்೘್∆ௌమ∆௛మ = ି∆௚೘∆௛మ  (34) 
where ∆h2 is the heat of fusion of a crystalline polymer, Tmb is the equilibrium melting point 
of a blend, and ∆S2 is the entropy of crystalline unit in a blend. 
In condition of a narrow temperature range between Tmb and Tm, which is the equilibrium 
melting point of a crystalline polymer, it is reasonable to assume that ∆h2 and ∆S2 are 
temperature independent hence; 
 ௠ܶ = ∆௛మ∆ௌమ (35) 
Introducing Equation (35) into Equation (34), so that Equation (34) can be expressed as the 
following equation; 
 ͳ − ்೘್೘் = ି∆௚೘∆௛మ  (36) 
A popular equation for ∆݃௠ is given by the classic Flory-Huggins mean field model. When a 
crystalline polymer is designated as the second component in the mixture, the lattice model 
gives; 
 ∆݃௠ = ோ்೘್௏మ௏భ ቄln ቀథమ௥మ ቁ + ቀ ଵ௥మ − ଵ௥భቁ߶ଵቅ + ோ்೘್௏మ௏భ ߣଶଵ߶ଵଶ (37) 
where Ø is the volume fraction and r is the chain length of each component denoted by the 
subscript used. V1 and V2 are the molar volume of the amorphous unit and the crystalline 
unit, respectively. ߣଶଵ is the polymer-polymer interaction parameter. R is the universal gas 
constant. Tmb is the temperature of the blends. The term in the square bracket represents 
contribution from the combinatorial entropy to the chemical potential changes per mole of 
crystalline unit in the mixture. As a major contribution to the molar free energy changes of 
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the mixture is provided by the enthalpy term, which is the second term of Equation (37). The 
entropy contribution is neglected, so that ∆݃௠ can be written in term of an approximate 
chemical potential form as displayed; 
 ∆݃௠ = ିோ்೘್௏మ௏భ ߣଶଵ߶ଵଶ (38) 
Substituting this approximated term into Equation (36) and rearranging, so that the 
resulting relationship is given as the following equation (Rostami 2000; Pimbert 2002); 
 ଵ்೘್ − ଵ்೘ = ିோ௏మఒమభథభమ୼௛మ௏భ  (39) 
According to ߣଶଵ = ஻௏భோ்೘್, Equation (39) can be written as the following expression (Nishi 
1975; Kuo 2001a); 
 ௠ܶ − ௠ܶ௕ = ି ೘்஻௏మ∅భమ∆௛మ  (40) 
where B is the interaction energy density characteristic of the polymer pair. The resulting 
equation, Equation (40), is the Nishi-Wang equation (Nishi 1975; Kuo 2001a; Kuo 2001b). 
From the investigation of the E2 melting point in solid dispersions containing E2 in ERS at 
the concentration range of 0-100 % w/w (Wiranidchapong 2006; Wiranidchapong 2008), the 
melting point depression as a function of composition was revealed as displayed in Figure 
11. The behavior of the E2 melting point in ERS solid dispersion was in accordance with that 
of a crystalline polymer blended with an amorphous polymer. Fitting experimental melting 
point of E2 in the dispersion to the Nishi-Wang equation exhibited good agreement between 
experimental values and predicted values, with randomly distributed residuals and the 
coefficient of determination (R2) of 0.9804. In addition, B value obtained from curve-fitting 
was -0.281 J/(g*cm3) (Wiranidchapong 2006; Wiranidchapong 2008). This indicated validity 
of the Nishi-Wang equation to predict the melting point of E2 in ERS solid dispersions, 
miscibility and interaction between E2 and ERS in the molten state. 
 
 
Fig. 11. The melting point depression of E2 in ERS solid dispersions at concentration range of 
0-100 % w/w investigated by MTDSC with the program of heating to 250 C, 5 K/min 
(Reproduced from Wiranidchapong, 2006). 
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5.3 The interaction between E2 and ERS in solid dispersion 
Both Kwei equation and Nishi-Wang equation predicted an existence of a specific 
interaction between E2 and ERS in the molten state. FTIR analysis was used to investigate 
the interaction between E2 and ERS in solid dispersions. FTIR spectra of E2 in ERS solid 
dispersions heated from 25-175 C at 5 K/min were compared with those of anhydrous E2 
and ERS as illustrated in Figure 12. The peak around 3530 cm-1, corresponding to free 
hydroxyl group absorption (Kuo 2001a; Kuo 2001b; Wiranidchapong 2006; Wiranidchapong 
2008; Wiranidchapong 2009), in FTIR spectrum of anhydrous E2 was also observed in that of 
75 % w/w E2 in ERS solid dispersion heated from 25-175 C. This indicated the water loss 
during the heating process, so that the free hydroxyl group of E2 was observed. 
Additionally, the band at 1732 cm-1 corresponding to the ester C=O stretching vibration of 
free carbonyl group (Pignatello 2002; Wiranidchapong 2006; Wiranidchapong 2008; 
Wiranidchapong 2009) was displayed in FTIR spectrum of ERS. 
The interaction between E2 and ERS was affirmed by the shift of broad band centered at 3434 
cm-1, attributed to O-H stretching of hydroxyl groups adjacent to C-17 positions in E2, to 3411 
cm-1 with a shoulder of the ester C=O stretching band in 75 %w/w E2 in ERS solid dispersion 
heated from 25-175 C. The shoulder around 1710 cm-1 corresponding to the hydrogen-bonded 
carbonyl group (Kuo 2001a; Kuo 2001b; Wiranidchapong 2006; Wiranidchapong 2008; 
Wiranidchapong 2009) suggested the inter-associated hydroxyl-carbonyl bond. The shoulder 
around 1710 cm-1 was also observed in FTIR spectra of 50 and 20 %w/w E2 in ERS solid 
dispersions heated from 25-175 C. Thus, the inter-associated hydrogen bonding between the 
free hydroxyl group of E2 and the ester C=O group of ERS was occurred in solid dispersion of 
E2 in ERS in the molten state in which water was removed from the E2 crystal. This occurrence 
was in accordance with the prediction by Kwei equation and Nishi-Wang equation. 
 
 
Fig. 12. FTIR spectra of E2 in ERS solid dispersions at concentration range of 0-100 % w/w 
heated from 25-175 C, 5 K/min, recorded at room temperature in the range of 3800-2600 
cm-1 (A) and 1800-900 cm-1 (B) (Reproduced from Wiranidchapong, 2008). 
www.intechopen.com
Solid State and Thermal Behavior of  
17-Estradiol in Ammonioethyl Methacrylate Ester Copolymer 427 
6. Conclusions 
E2 is an essential steroid hormone that regulates numerous endocrine functions secreted 
during the reproductive years. Early phase in menopause symptoms can be relieved by 
administration of E2 mimic the menstrual cycle. The treatment goal requires the lowest 
effective dose delivered into the blood circulation at a constant rate. This manner can 
prevent estrogen-insufficient symptoms and/or estrogen-excess symptoms according to 
peak and trough pattern of plasma estrogen concentration versus time profile. Polymer 
matrix diffusion controlled-release drug delivery system can provide a relatively constant 
rate of E2 release. The accomplishment of a constant release is a result of the inherent 
solubility of E2 providing the drug dissolution controlled-release system. 
Polymorphic state of E2 dispersing in the polymer matrix directly affects the solubility of E2 
in the surrounding medium and consequently the rate of E2 released. Thermal analysis can 
be used to verify the polymorphic state of E2 dispersing in the polymer matrix. In the case of 
amorphous E2 dispersing in the polymer matrix, the Tg behavior can be described by the 
principle of Gordon-Taylor equation. On the other hand, the melting point depression of 
crystalline E2 dispersing in the polymer matrix can be described by the Flory-Huggins 
theory. Additionally the interaction between E2 and ERS used as a polymer matrix can be 
predicted by both theories. 
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